GlassScriptPhysician profile
David L Green
NPI 1861846313
$5,361.83
in general payments reported to CMS, 2019-2025
34 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $486 · 2021: $401 · 2022: $269 · 2023: $767 · 2024: $1,461 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,535.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,194.45 | 2019-2025 | |
| Abbvie INC. | $1,004.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $738.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $357.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.95 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $204.33 | 2019-2020 | |
| Novo Nordisk INC | $181.36 | 2020-2025 | Rybelsus, Ozempic, Saxenda |
| Idorsia Pharmaceuticals US INC | $145.60 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $130.53 | 2025 | Zoryve |
| Abbott Laboratories | $96.10 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Exact Sciences Corporation | $84.08 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $78.25 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $65.38 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.78 | 2019-2024 | Synjardy, Jardiance |
| Amarin Pharma, INC. | $56.38 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.46 | 2019-2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $54.99 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.82 | 2025 | Caplyta |
| Lundbeck LLC | $42.42 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $34.73 | 2019-2023 | Myrbetriq |
| Inspire Medical Systems, INC. | $32.62 | 2023 | Inspire |
| Sumitomo Pharma America, INC. | $31.69 | 2023 | Gemtesa |
| Genentech USA, INC. | $30.32 | 2019-2020 | |
| Esperion Therapeutics, INC. | $29.55 | 2020-2021 | |
| Glaxosmithkline, LLC. | $29.38 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $24.90 | 2023 | |
| Medtronic, INC. | $23.09 | 2023 | Intellis Adaptivestim |
| Shield Therapeutics INC | $20.51 | 2023 | Accrufer |
| Axsome Therapeutics, INC. | $20.11 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $16.48 | 2025 | |
| Supernus Pharmaceuticals, INC. | $14.70 | 2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $14.45 | 2022 | |
| Eisai INC. | $13.83 | 2019 | |
| Gilead Sciences, INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.